The data also suggest that a certain dose or agent that regulates VEGF-mediated signaling triggered through VEGFR2 in retinal endothelial cells might be a possible therapeutic approach to inhibit IVNV, facilitate physiologic retinal vascular development, and reduce the likelihood of recurrent IVNV in ROP. Here, VEGFA is linked to retinopathy of prematurity.